

Polyclonal Anti-Integrin β2

Catalogue No. PA1124

Immunogen

Lot No. 08J01

A synthetic peptide mapping at the N-terminal of human Integrin $\beta 2$, different from the related mouse sequence by five amino acids.

Ig type: rabbit IgG

Purity

Size: 100µg/vial

Immunogen affinity purified.

Specificity

Application

Human, rat.

Western blot

Western blot

No cross reactivity with other

At 1-2 μ g/ml with the appropriate system to detect Integrin β 2 in cells and tissues.

proteins.

Immunohistochemistry(P)

Recommended application

At 1-2 μ g/ml to detect Integrin β 2 in formalin fixed and paraffin

embedded tissues. Boiling the sections is required.

Immunohistochemistry(P)

Optimal dilutions should be determined by end user.

Other applications have not been tested.

Contents

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na $_2$ HPO $_4$, 0.05mg Thimerosal, 0.05mg NaN $_3$.

Reconstitution

0.2ml of distilled water will yield a concentration of 500µg/ml.

Storage

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time.

Relative detection systems

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IH(P).

Switzerland

Deutschland

Fax: + 1 949 265 7703



BACKGROUND

The beta-2 integrin chain gene is designated ITGB2 and the leukocyte antigen has been designated CD18. The 3 alpha integrin chains associated individually with the beta-2 chain as a heterodimer have gene designations of ITGAL, ITGAM, and ITGAX, and leukocyte antigen designations of CD11A, CD11B, and CD11C, respectively. The expression of CD18 was increased in lymphoblastoid cells from persons with Down syndrome, consistent with the location of the gene on chromosome 21¹. The ITGB2 gene spans approximately 40 kb and contains 16 exons and all exon/intron boundaries conform to the GT/AG splicing consensus². Furthermore, ITGB2 was constitutively clustered. Although it was expressed on the cell surface at normal levels and was capable of function following extracellular stimulation, it could not be activated via the "inside-out" signaling pathways³.

REFERENCE

- 1.Taylor, G. M.; Williams, A.; D'Souza, S. W.; Fergusson, W. D.; Donnai, D.; Fennell, J.; Harris, R.: The expression of CD18 is increased on trisomy 21 (Down syndrome) lymphoblastoid cells. *Clin. Exp. Immun.* 71: 324-328, 1988.
- 2.Weitzman, J. B.; Wells, C. E.; Wright, A. H.; Clark, P. A.; Law, S. K. A.: The gene organisation of the human beta-2 integrin subunit (CD18). *FEBS Lett.* 294: 97-103, 1991.
- 3.McDowall, A.; Inwald, D.; Leitinger, B.; Jones, A.; Liesner, R.; Klein, N.; Hogg, N.: A novel form of integrin dysfunction involving beta-1, beta-2, and beta-3 integrins. *J. Clin. Invest.* 111: 51-60, 2003.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE.

Deutschland

Fax: + 1 949 265 7703